WO2007109515A3 - Mutations and polymorphisms of knockdown resistance polypeptide - Google Patents

Mutations and polymorphisms of knockdown resistance polypeptide Download PDF

Info

Publication number
WO2007109515A3
WO2007109515A3 PCT/US2007/064115 US2007064115W WO2007109515A3 WO 2007109515 A3 WO2007109515 A3 WO 2007109515A3 US 2007064115 W US2007064115 W US 2007064115W WO 2007109515 A3 WO2007109515 A3 WO 2007109515A3
Authority
WO
WIPO (PCT)
Prior art keywords
kdr
mutations
polymorphisms
mutant
various aspects
Prior art date
Application number
PCT/US2007/064115
Other languages
French (fr)
Other versions
WO2007109515A2 (en
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2007109515A2 publication Critical patent/WO2007109515A2/en
Publication of WO2007109515A3 publication Critical patent/WO2007109515A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the KDR gene. The invention provides new KDR mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the KDR mutations of the invention, expression vectors encoding the KDR mutant polypeptides of the invention and organisms that express the KDR mutant and polymorphic polynucleotides and/or KDR mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the KDR mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
PCT/US2007/064115 2006-03-20 2007-03-16 Mutations and polymorphisms of knockdown resistance polypeptide WO2007109515A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78413106P 2006-03-20 2006-03-20
US60/784,131 2006-03-20

Publications (2)

Publication Number Publication Date
WO2007109515A2 WO2007109515A2 (en) 2007-09-27
WO2007109515A3 true WO2007109515A3 (en) 2008-05-29

Family

ID=38523177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/064115 WO2007109515A2 (en) 2006-03-20 2007-03-16 Mutations and polymorphisms of knockdown resistance polypeptide

Country Status (1)

Country Link
WO (1) WO2007109515A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374954T3 (en) * 2006-11-16 2012-02-23 Genentech, Inc. GENETIC VARIATIONS ASSOCIATED WITH TUMORS.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1203827A2 (en) * 2000-11-03 2002-05-08 AstraZeneca AB Polymorphisms in the human KDR gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1203827A2 (en) * 2000-11-03 2002-05-08 AstraZeneca AB Polymorphisms in the human KDR gene

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ASTA FÖRSTI ET AL: "Polymorphisms in the KDR and POSTN Genes: Association with Breast Cancer Susceptibility and Prognosis", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 101, no. 1, 29 June 2006 (2006-06-29), pages 83 - 93, XP019464116, ISSN: 1573-7217 *
BARDELLI ALBERTO ET AL: "Mutational analysis of the tyrosine kinome in colorectal cancers.", SCIENCE (WASHINGTON D C), vol. 300, no. 5621, 9 May 2003 (2003-05-09), pages 949, XP002473151, ISSN: 0036-8075 *
DATABASE EMBL 26 February 2008 (2008-02-26), "VEGF2_HUMAN", XP002473155 *
KARIYAZONO HIDEHIKO ET AL: "Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease", PEDIATRIC RESEARCH, vol. 56, no. 6, December 2004 (2004-12-01), pages 953 - 959, XP002473154, ISSN: 0031-3998 *
LEE JONG WOO ET AL: "Kinase domain mutation of NTRK3 gene is uncommon in gastric carcinomas", ACTA ONCOLOGICA (STOCKHOLM), vol. 44, no. 8, December 2005 (2005-12-01), pages 924 - 925, XP002473153, ISSN: 0284-186X *
SJOEBLOM TOBIAS ET AL: "The consensus coding sequences of human breast and colorectal cancers", SCIENCE (WASHINGTON D C), vol. 314, no. 5797, October 2006 (2006-10-01), pages 268 - 274, XP002473152, ISSN: 0036-8075 *
WALTER JEFFREY W ET AL: "Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma", GENES CHROMOSOMES AND CANCER, vol. 33, no. 3, March 2002 (2002-03-01), pages 295 - 303, XP002473150, ISSN: 1045-2257 *

Also Published As

Publication number Publication date
WO2007109515A2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
NZ600235A (en) Methods and compositions for the assessment of drug response
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
MX2009003562A (en) Elisa for vegf.
WO2006135879A3 (en) Diagnosis and prognosis of diabetes
WO2005033652A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
MX2019008675A (en) Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof.
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
WO2006073682A3 (en) Diagnostic test
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
NZ596614A (en) Diagnosis and treatment of alzheimer's disease
WO2006110478A3 (en) Mutations and polymorphisms of epidermal growth factor receptor
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
WO2007022041A3 (en) Mutations and polymorphisms of hdac3
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
ATE432997T1 (en) THERAPY MONITORING FOR TUMORS USING ACC133 MRNA
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
WO2007038073A3 (en) Mutations and polymorphisms of hdac11
WO2007030454A3 (en) Mutations and polymorphisms of hdac9
WO2007058992A3 (en) Mutations and polymorphisms of hdac6

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07779827

Country of ref document: EP

Kind code of ref document: A2